By Ann George

Introduction:

The pandemic that began in late 2019 has devastated the world, resulting in millions of infections and deaths all over the globe. Beyond the immediate health crisis that it engendered, this pandemic has unearthed and exacerbated existing disparities in the healthcare system, especially in the area of vaccine distribution. Wealthier nations competed for a large share of vaccine supplies, thereby leaving poorer and middle-income nations with little access. This phenomenon, sometimes called the “vaccine apartheid,” has further accentuated the glaring inequalities in global health.

The issues of vaccine apartheid and healthcare disparities are examined in this paper and their implications for global health are discussed. Vaccine nationalism is examined, whereby countries consider their populations first and foremost in the distribution of vaccines, ignoring the needs of others. This paper further scrutinises the roles of international organisations in fighting these disparities, notably the World Health Organisation (WHO). The ethical considerations of vaccine equity, as well as the moral obligation to ensure access for everyone, are then explored. Finally, the penultimate section describes proposed solutions to address these disparities, stressing that global cooperation and sustainable financing are necessary to ensure fair access to vaccines and healthcare services.

Vaccine Apartheid and Disparities in Healthcare Access:

The term “vaccine apartheid” indicates the systemic inequalities in the distribution of vaccines globally. In this, wealthy nations can secure the bulk of the vaccine supplies, whereas low- and middle-income countries (LMICs) are pushed to the margins with limited access. This disparity was glaringly evident during the COVID-19 pandemic, giving rise to an urgent need for the equitable distribution of vaccines as an issue of global health security.

Historically, low—and middle-income countries have faced the challenges of limited healthcare infrastructure, political instability, and economic impediments, which have created barriers to the acquisition and distribution of vaccines. These systemic challenges perpetuated health inequities and hampered access to other essential medical resources, including vaccines.

The COVID-19 pandemic revealed stark inequity in terms of vaccine distribution. For quite some time, the high-income countries (HICs) were able to obtain large quantities of vaccines, sometimes more than what they needed for their population, while many of the low- and middle-income countries (LMICs) faced hurdles in obtaining sufficient doses. For example, as of mid-2021, more than 80% of global doses administered were HICs, making LMICs the recipients of less than 20% of the dose.

Such disparities have far-reaching health and economic consequences. For instance, in Africa, the slow rollout of vaccines has been closely linked with the emergence of new variants, including Omicron, which bears import for the world. Because vaccine availability in LMICs has not been widespread, the virus has been allowed to continue circulating, increasing the risk of mutation to a form that would not be subject to immunity from existing vaccines.

To remedy such unevenness, COVAX tried to bridge the gap. However, funding shortages, logistic problems, and vaccine nationalism have thwarted its success. As recently as late 2025, Gavi, The Vaccine Alliance, stated that it had only managed to mobilise $2.4 billion of the $9 billion needed for the next funding cycle, thus echoing the financial challenge still present in underpinning vaccine equity.

The act of vaccine nationalism entails the practice of some governments in agreements with pharmaceutical manufacturers to secure vaccines for their populations with little or no regard for their equitable distribution across the globe. The advent of vaccine nationalism was during the COVID-19 pandemic when countries, especially wealthier ones, had gone into bilaterally negotiated deals to ensure early access to vaccines.  The consequences of vaccine nationalism on the equitable distribution of health resources worldwide have been huge. High-income countries acquired much of the vaccine supply, leaving low- and middle-income countries with little access. By April 2021, 87% of global COVID-19 vaccine supplies were reported to have been administered in high-income countries (HICs), while low-income countries had only received 0.2% from the WHO. This distribution is inequitable within and across borders, and in as much as it aids the further spread of the virus and mutations in poorly vaccinated areas, it aggravates prevailing health disparities in the remaining States or regions and causes socio – economic injustices to vulnerable populations.

COVAX was established to counter vaccine nationalism and strive for just access. It seeks to facilitate the rapid development and manufacture of COVID-19 vaccines and guarantee fair and equitable access for every nation.  Despite these efforts in trying to rectify an unacceptable disparity, COVAX fell short in some areas, including supply chain problems, vaccine nationalism, and export restrictions from surrounding countries. Notwithstanding COVAX’s good work in supplying vaccines to many countries, the low demand and uptake of vaccines, particularly in low-income nations, emphasises the need to further enhance international cooperation and support to close the vaccine equity gap. These days, global organisations, including the WHO, UNICEF, and Gavi, need to be at the forefront of enhancing health equity, specifically related to ensuring equal access to vaccines during the COVID-19 pandemic. 

WHO has played a global role in the establishment of vaccination targets to promote equitable access to vaccines. In 2021, it set 70 per cent global vaccine uptake by June 2022 as a target. As one of the largest vaccine buyers globally, UNICEF has played a significant role in procurement and distribution. Working under the Pan American Health Organisation (PAHO) RevolvingFund, UNICEF managed the procurement and supply of COVID-19 vaccine doses to COVAX. Gavi co-led COVAX to accelerate the development and manufacturing of COVID-19 vaccines and ensure equitable access in every country around the world.

Despite this, there were ongoing challenges. Vaccine nationalism, combined with issues in the supply chain, became obstacles against equitably distributing vaccines. By the middle of 2021, COVAX had shipped almost 200 million doses of vaccines to about 140 countries, which fell short of the initial target. 

For more comprehensive future responses, international organisations need to work on strengthening the global supply chain, regional manufacturing of vaccines, and transparent communication with member states. Intellectual property rights that stifle vaccine affordability and access should also be reconsidered.  The pandemic displayed some very serious ethical challenges faced by global health, most notably in the field of vaccine distribution whereby vaccine access is treated as a matter of equity, justice, and human rights, access to life-saving interventions should never be determined by a nation’s wealth or geopolitical standing. The phenomenon of vaccine nationalism whereby countries put the interests of their populations first is very often characterised by the hoarding of vaccines to the detriment of populations in more dire need, thus aggravating health inequalities across the globe. 

Protecting citizens is a significant duty for all governments but global health equity is also, in some ways, an ethical imperative. The more national populations are prioritised, the more the global effort will be hampered by new areas left unvaccinated, which become the countries of greatest risk for mutated variants harmful to international health.  Both nations and international organisations bear the responsibility for ensuring equitable access to vaccines according to principles such as non-discrimination, social justice, and health disparity reduction. Ethical principles require the implementation of frameworks for fair allocation that consider populations at high risk whether or not they are nationals; such an approach would prove more beneficial for a global response during times of health crisis.

IP waivers to ensure higher access to COVID-19 vaccines have been proposed that would allow manufacturers in LMICs to produce vaccines without legal encumberment. In October 2020, India and South Africa approached the WTO and requested that it permit all countries to forego the enforcement of patents on COVID-19 technologies during the pandemic. The U.S. supported this initiative in May 2021, while a waiver was approved by WTO by June 2022 concerning patents on COVID-19 vaccines. Nonetheless, discussions about the waiver’s parameters and its implications for innovation in pharmaceuticals are ongoing.  

Increased financial support is vital to global health initiatives, especially in LMICs. The World Health Organisation estimated the LMICs would need to increase health spending by at least 1% of their gross domestic product before the onset of the pandemic to achieve health-related Sustainable Development Goals. Global health funding increased from $10 billion in 1996 to $41 billion in 2019 amid these disparities. More recently, funding freezes such as the U.S. halt on foreign aid have disrupted essential health services and demonstrate the necessity for consistent and increased investments.  

The need for effective distribution in the developing world is a strong health infrastructure. Generally, provision of logistics, training of workers, and strengthening of facilities are key components. With the infrastructure in the hands of such efforts as vaccination, such massive investment prepares these nations for health emergencies to come. For instance, the Global Fund efforts have saved millions of lives through strengthening health systems across the world.

Governments, private sectors, and international organisations must collaborate across borders to redress health inequities. Public-private partnerships, for example, promote the sharing of resources and technology transfer so that health emergencies can be addressed in a coordinated manner. Gavi, the Vaccine Alliance, is an example of such collaboration, putting resources together to fund vaccination programs in LMICs. However, funding constraints such as the U.S. withdrawal from the World Health Organisation exposed the fragility of these efforts and must, however, maintain continued commitment to Gavi, focusing on intervening issues like COVID-19.

Conclusion:

The COVID-19 pandemic laid bare the long-standing inequities encapsulated in global health. Though ambitious programs spearheaded by international organisations like COVAX and WHO sought to change the situation, structural impediments, including vaccine nationalism, intellectual property limitations, and a lack of financial resources, each created barriers to equitable distribution. 

A wide-ranging set of waivers for intellectual property must be adopted for regional vaccine manufacturing, together with sustained financial commitments from developed countries to strengthen health systems in low- and middle-income countries. Equally important are transparent global governance mechanisms that prioritise equity over profit motives.

Vaccine apartheid is more than a question of health security; it is a question of global solidarity. Unless profound change occurs, the next time a health crisis emerges, it will likely follow the same path as that of COVID-19, with already marginalised groups accounting for systemic injustice. True global health justice must emanate from continued collaboration, ethical policy-making, and greater commitments as barriers to equality are pulled down.

Author’s Bio:  

Ann Susan George is a second-year B.A. LL. B student at O.P. Jindal Global Law School. Her interests include public policy, human rights and law.

Image Source : https://www.openglobalrights.org/vaccine-apartheid-global-inequities-in-covid-vaccine-pro duction-and-distribution/